Northern Trust Corp Purchases 243,522 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Northern Trust Corp lifted its holdings in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,875,160 shares of the company's stock after buying an additional 243,522 shares during the quarter. Northern Trust Corp owned 0.77% of Standard BioTools worth $5,032,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Takeda Pharmaceutical Co. Ltd. acquired a new position in Standard BioTools in the fourth quarter valued at $29,000. Two Sigma Securities LLC purchased a new stake in Standard BioTools during the fourth quarter valued at about $30,000. Aquatic Capital Management LLC purchased a new stake in Standard BioTools during the fourth quarter valued at about $45,000. Cibc World Markets Corp purchased a new stake in Standard BioTools during the fourth quarter valued at about $48,000. Finally, Simon Quick Advisors LLC purchased a new stake in Standard BioTools during the fourth quarter valued at about $54,000. 53.74% of the stock is owned by institutional investors and hedge funds.

Standard BioTools Trading Up 11.8%

LAB traded up $0.11 during trading hours on Tuesday, hitting $1.03. The company's stock had a trading volume of 2,154,581 shares, compared to its average volume of 2,139,503. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.65. The firm has a market capitalization of $391.22 million, a PE ratio of -1.45 and a beta of 1.80. The company has a 50-day simple moving average of $1.11 and a 200 day simple moving average of $1.43.

Insider Buying and Selling

In related news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the acquisition, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. The trade was a 8.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 37,971 shares of company stock valued at $38,540. Corporate insiders own 23.16% of the company's stock.

Analysts Set New Price Targets

Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.